Azacitidine prolongs overall survival and reduces infections and hospitalizations in patients with WHO-defined acute myeloid leukaemia compared with conventional care regimens: an update

Azacitidine (AZA), as demonstrated in the phase III trial (AZA-001), is the first MDS treatment to significantly prolong overall survival (OS) in higher risk MDS pts ((2007) Blood 110 817). Approximately, one-third of the patients (pts) enrolled in AZA-001 were FAB RAEB-T (≥20–30% blasts) and now me...

Descripción completa

Detalles Bibliográficos
Autores principales: Fenaux, P, Mufti, GJ, Hellström-Lindberg, E, Santini, V, Gattermann, N, Sanz, G, List, AF, Gore, SD, Seymour, JF, Backstrom, J, Zimmerman, L, McKenzie, D, Beach, CL, Silverman, LB
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2008
Materias:
Short Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234073/
https://www.ncbi.nlm.nih.gov/pubmed/22275991
http://dx.doi.org/10.3332/ecancer.2008.121

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234073/
https://www.ncbi.nlm.nih.gov/pubmed/22275991
http://dx.doi.org/10.3332/ecancer.2008.121

Ejemplares similares